Dossier assessment
Apremilast (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Apremilast (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Apremilast (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Children and adolescents from the age of 6 years and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for systemic therapy
Added benefit not proven
Project details
- Project no.
- A24-112
- Commission
- Commission awarded on 18.11.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-112_en
Connected Projects
-
Dossier assessment
Apremilast (Behçet’s disease) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Apremilast - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed